Mutant p53 drives invasion by promoting integrin recycling.

By P. Muller, P. Caswell, B. Doyle, Marcin P Iwanicki, E. Tan, S. Karim, N. Lukashchuk, David A. Gillespie, R. Ludwig, Pauline Gosselin and 5 more. Cell, 2009

812 citations recorded by the source corpus.

Subfields: Immunology and Allergy, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/bd54fa96e4c9bfa7ce4053fa2d86c43738256661

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology and Allergy

1. J. Erler

In Molecular Biology

1. Carol Prives
2. Moshe Oren
3. William A. Freed-Pastor
4. Varda Rotter
5. R. Brosh
6. J. Erler
7. Pier Paolo Di Fiore
8. M. von Zastrow

In Oncology

1. Moshe Oren
2. Carol Prives
3. William A. Freed-Pastor
4. Varda Rotter
5. R. Brosh
6. J. Erler
7. Vladimir N Uversky

Citations in the corpus

• Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. (2011, background): “An additional mechanism through which mutant p53 was shown to augment cell invasion is via the inhibition of TAp63, thus promoting TGFβ-induced metastasis and boosting integrin recycling pathways that promote invasiveness.(83,84) Another possible GOF effect of mutant p53 on tumor progression may be ”
• Mutant p53: one name, many proteins. (2012, background): “…stem cell characteristics (Mizuno et al. 2010; Sarig et al. 2010), disruption of tissue architecture (Freed-Pastor et al. 2012), and angiogenesis (Fontemaggi et al. 2009), as well as migration, invasion, and metastasis (Hsiao et al. 1994; Adorno et al. 2009; Muller et al. 2009; Noll et al. 2011).”
• Endocytosis, Signaling, and Beyond (2014, background): “…that the oncogenic potential of TP53 point mutants found in human cancer may partly lie in their regulatory role within the endocytic pathway (Muller et al. 2009), because it has recently been shown that these mutants not only lose tumor suppression activity, but they also promote invasion…”
• Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy (2015, positive): “Our previous studies have shown key roles for mutant p53 in driving the mechanics of invasion and migration (integrin and met recycling) (Muller et al , 2009, 2013).”